Docetaxel
Product Images NDC 72485-215

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Docetaxel (NDC 72485-215). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Armas Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 01)

Chemical structure diagram of docetaxel showing the molecular arrangement including multiple rings, hydroxyl groups, and side chains as depicted in the image.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 02)

A line graph showing Disease-Free Survival (DFS) Probability percentage over time in months for two treatment groups labeled TAC and FAC. The y-axis represents DFS Probability (%) from 0 to 100, and the x-axis represents Disease-Free Survival Time (months) from 0 to 66. Both lines show a decreasing trend over time, with TAC generally higher than FAC.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 03)

A line graph depicting survival probability (%) over survival time in months for two groups labeled TAC and FAC. The x-axis represents time from 0 to 66 months, and the y-axis shows survival probability from 0 to 100%. The graph compares the survival trends of both groups over time.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 04)

A survival curve graph showing cumulative probability versus survival time in months for two groups labeled T75 and BSC. The figure includes a log-rank p-value of 0.010 indicating statistical comparison between the groups. The y-axis represents cumulative probability from 0 to 1, and the x-axis represents survival time up to 21 months.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 05)

A survival curve graph comparing cumulative probability of survival over time in months between two groups labeled T75 and V/1. The graph includes a log-rank p-value of 0.13 indicating overall survival comparison.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 06)

A survival probability curve chart depicting survival time in months on the horizontal axis and survival probability on the vertical axis. Two lines represent different treatment groups labeled T75 q3w and M q3w, showing their respective survival trends over a period up to 30 months.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 07)

A Kaplan-Meier survival probability curve comparing two groups labeled TFC and CF over a period of 24 months. The vertical axis shows probability in percentage, and the horizontal axis shows time in months, illustrating differences in survival probabilities between the two groups.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 08)

A line graph showing survival probability (%) over survival time (months) for two groups labeled TFC and CF. The graph illustrates decreasing survival probability as time progresses from 0 to 36 months for both groups, with distinct lines representing each group.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 09)

A line graph depicting progression free survival (PFS) probability over time in months. The graph compares two groups labeled TFC and PF, showing survival probabilities decreasing over 42 months with TFC consistently higher than PF.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 10)

A survival probability graph comparing two groups, TPF and PF, over time in months. The y-axis represents survival probability (%) from 0 to 100, and the x-axis shows survival time up to 72 months. Two survival curves illustrate trends for TPF and PF groups, with TPF generally showing higher survival probability across the timeline.*

FDA Label Image

Image (767b6901 F1ec 4d39 Bc9f D808f2ec95a3 11)

A Kaplan-Meier survival curve showing survival probability (%) over survival time (months) for two patient groups, TPF (n=255) and PF (n=246). The graph includes the number of patients at risk at various time points up to 72 months, comparing the two groups' survival rates.*

FDA Label Image

Doce80 (Docelbl80)

Docetaxel Injection, USP 80 mg/4 mL (20 mg/mL) vial and carton labels from Armas Pharmaceuticals Inc. The labels indicate the product is ready to add to infusion solution, for intravenous infusion only, and contains 4 mL single-use vial. The vial and carton also display dosage information, manufacturer and distributor details, barcodes, and warnings about the cytotoxic nature of the agent.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.